Cytomegalovirus and Chlamydia pneumoniae as predictors for adverse events and angina pectoris after percutaneous coronary intervention
The aim of our study was to investigate the influence of prior cytomegalovirus (CMV) or Chlamydia pneumoniae (CP) infection on prognosis after percutaneous coronary intervention (PCI). Using the enzyme-linked immunosorbent assay technique preprocedural anti-CMV immunoglobulin G and anti-CP immunoglo...
Gespeichert in:
| Veröffentlicht in: | The American heart journal 2004-10, Vol.148 (4), p.670-675 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 675 |
|---|---|
| container_issue | 4 |
| container_start_page | 670 |
| container_title | The American heart journal |
| container_volume | 148 |
| creator | Rahel, Braim M. Visseren, Frank L.J. Suttorp, Maarten-Jan Plokker, Thijs H.W. Kelder, Johannes C. de Jongh, Bartelt M. Diepersloot, Rob J.A. Verkooyen, Roel P.A.J. Bouter, K.Paul |
| description | The aim of our study was to investigate the influence of prior cytomegalovirus (CMV) or
Chlamydia pneumoniae (CP) infection on prognosis after percutaneous coronary intervention (PCI).
Using the enzyme-linked immunosorbent assay technique preprocedural anti-CMV immunoglobulin G and anti-CP immunoglobulin A (CP IgA), immunoglobulin M, and immunoglobulin G antibodies were measured. Repeat anginal complaints and major adverse clinical events (MACE), including PCI, coronary artery bypass grafting, myocardial infarction, and death, were recorded at 8-month follow-up.
Six hundred consecutive patients were included after successful PCI. Sixty-four percent of the patients were stented. The mean age was 61.6 years, and 68.9% were male. The rate of seropositivity for CP IgA in patients with MACE as compared with patients without MACE was 50.9% versus 35.4% (
P = .0276). In patients with repeat anginal complaints, CP IgA seropositivity was 41.6% versus 34.6% in patients without repeat angina (
P = .1057). The negative effect of CP on prognosis was confirmed after calculating the odds ratios for MACE (1.9, 95% CI 1.1–3.3). The rates of seropositivity for anti-CMV immunoglobulin G were not significantly different between both groups, although we found an association between infectious burden and repeat angina pectoris (odds ratio 1.8, 95% CI 1.1–3.0).
We conclude that preprocedural seropositivity of CP IgA is a risk factor for MACE and angina pectoris after PCI. Although no such relation was found for CMV alone, the cumulative infectious burden was also related to these clinical manifestations of restenosis. |
| doi_str_mv | 10.1016/j.ahj.2004.04.018 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66927883</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002870304002194</els_id><sourcerecordid>3237558881</sourcerecordid><originalsourceid>FETCH-LOGICAL-c407t-9c55bec6986a35ef3dabae478bed1dd6ce89a81891c354f6c88f3c567f6d54213</originalsourceid><addsrcrecordid>eNp9kd-q1DAQxoMonvXoA3gjAdG7rkmbpCleyeI_OOCNXofZZHpOSpusSbuwL-Bzm9KFA14IA2GS3zczmY-Q15ztOePqw7CHh2FfMyb2a3D9hOw469pKtUI8JTvGWF3pljU35EXOQ0lVrdVzcsOlkJ3suh35c7jMccJ7GOPZpyVTCI4eHkaYLs4DPQVcphg8IIVMTwmdt3NMmfYxUXBnTBkpnjHMmxLCvQ9Fhivly10_YyppsssMAWNpYGOKAdKF-lDeVqmP4SV51sOY8dX1vCW_vnz-efhW3f34-v3w6a6ygrVz1Vkpj2hVpxU0EvvGwRFQtPqIjjunLOoONNcdt40UvbJa942Vqu2Vk6LmzS15v9U9pfh7wTybyWeL47gNZ5Tq6lbrpoBv_wGHuKRQZjNcMiFkzTkrFN8om2LOCXtzSn4qnzOcmdUiM5hikVktMmtwXTRvrpWX44TuUXH1pADvrgBkC2OfIFifHznF21pJUbiPG4dlYWePyWTrMdjiUSr7Ny76_4zxF-c8sgg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1504452110</pqid></control><display><type>article</type><title>Cytomegalovirus and Chlamydia pneumoniae as predictors for adverse events and angina pectoris after percutaneous coronary intervention</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Rahel, Braim M. ; Visseren, Frank L.J. ; Suttorp, Maarten-Jan ; Plokker, Thijs H.W. ; Kelder, Johannes C. ; de Jongh, Bartelt M. ; Diepersloot, Rob J.A. ; Verkooyen, Roel P.A.J. ; Bouter, K.Paul</creator><creatorcontrib>Rahel, Braim M. ; Visseren, Frank L.J. ; Suttorp, Maarten-Jan ; Plokker, Thijs H.W. ; Kelder, Johannes C. ; de Jongh, Bartelt M. ; Diepersloot, Rob J.A. ; Verkooyen, Roel P.A.J. ; Bouter, K.Paul</creatorcontrib><description>The aim of our study was to investigate the influence of prior cytomegalovirus (CMV) or
Chlamydia pneumoniae (CP) infection on prognosis after percutaneous coronary intervention (PCI).
Using the enzyme-linked immunosorbent assay technique preprocedural anti-CMV immunoglobulin G and anti-CP immunoglobulin A (CP IgA), immunoglobulin M, and immunoglobulin G antibodies were measured. Repeat anginal complaints and major adverse clinical events (MACE), including PCI, coronary artery bypass grafting, myocardial infarction, and death, were recorded at 8-month follow-up.
Six hundred consecutive patients were included after successful PCI. Sixty-four percent of the patients were stented. The mean age was 61.6 years, and 68.9% were male. The rate of seropositivity for CP IgA in patients with MACE as compared with patients without MACE was 50.9% versus 35.4% (
P = .0276). In patients with repeat anginal complaints, CP IgA seropositivity was 41.6% versus 34.6% in patients without repeat angina (
P = .1057). The negative effect of CP on prognosis was confirmed after calculating the odds ratios for MACE (1.9, 95% CI 1.1–3.3). The rates of seropositivity for anti-CMV immunoglobulin G were not significantly different between both groups, although we found an association between infectious burden and repeat angina pectoris (odds ratio 1.8, 95% CI 1.1–3.0).
We conclude that preprocedural seropositivity of CP IgA is a risk factor for MACE and angina pectoris after PCI. Although no such relation was found for CMV alone, the cumulative infectious burden was also related to these clinical manifestations of restenosis.</description><identifier>ISSN: 0002-8703</identifier><identifier>EISSN: 1097-6744</identifier><identifier>DOI: 10.1016/j.ahj.2004.04.018</identifier><identifier>PMID: 15459599</identifier><identifier>CODEN: AHJOA2</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Angina pectoris ; Angina Pectoris - etiology ; Angioplasty ; Angioplasty, Balloon, Coronary ; Biological and medical sciences ; Cardiology. Vascular system ; Chlamydophila Infections - complications ; Chlamydophila pneumoniae - isolation & purification ; Coronary Artery Bypass ; Coronary Disease - complications ; Coronary Disease - therapy ; Coronary heart disease ; Coronary Restenosis - etiology ; Cytomegalovirus ; Cytomegalovirus - isolation & purification ; Cytomegalovirus Infections - complications ; Disease-Free Survival ; Female ; Fibrinolytic Agents - therapeutic use ; Follow-Up Studies ; Heart ; Heart attacks ; Humans ; Male ; Medical sciences ; Middle Aged ; Myocardial Infarction - etiology ; Prognosis ; Recurrence ; Stents</subject><ispartof>The American heart journal, 2004-10, Vol.148 (4), p.670-675</ispartof><rights>2004 Elsevier Inc.</rights><rights>2004 INIST-CNRS</rights><rights>Copyright Elsevier Limited Oct 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c407t-9c55bec6986a35ef3dabae478bed1dd6ce89a81891c354f6c88f3c567f6d54213</citedby><cites>FETCH-LOGICAL-c407t-9c55bec6986a35ef3dabae478bed1dd6ce89a81891c354f6c88f3c567f6d54213</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1504452110?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>315,781,785,3551,27929,27930,46000,64390,64392,64394,72474</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16172654$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15459599$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rahel, Braim M.</creatorcontrib><creatorcontrib>Visseren, Frank L.J.</creatorcontrib><creatorcontrib>Suttorp, Maarten-Jan</creatorcontrib><creatorcontrib>Plokker, Thijs H.W.</creatorcontrib><creatorcontrib>Kelder, Johannes C.</creatorcontrib><creatorcontrib>de Jongh, Bartelt M.</creatorcontrib><creatorcontrib>Diepersloot, Rob J.A.</creatorcontrib><creatorcontrib>Verkooyen, Roel P.A.J.</creatorcontrib><creatorcontrib>Bouter, K.Paul</creatorcontrib><title>Cytomegalovirus and Chlamydia pneumoniae as predictors for adverse events and angina pectoris after percutaneous coronary intervention</title><title>The American heart journal</title><addtitle>Am Heart J</addtitle><description>The aim of our study was to investigate the influence of prior cytomegalovirus (CMV) or
Chlamydia pneumoniae (CP) infection on prognosis after percutaneous coronary intervention (PCI).
Using the enzyme-linked immunosorbent assay technique preprocedural anti-CMV immunoglobulin G and anti-CP immunoglobulin A (CP IgA), immunoglobulin M, and immunoglobulin G antibodies were measured. Repeat anginal complaints and major adverse clinical events (MACE), including PCI, coronary artery bypass grafting, myocardial infarction, and death, were recorded at 8-month follow-up.
Six hundred consecutive patients were included after successful PCI. Sixty-four percent of the patients were stented. The mean age was 61.6 years, and 68.9% were male. The rate of seropositivity for CP IgA in patients with MACE as compared with patients without MACE was 50.9% versus 35.4% (
P = .0276). In patients with repeat anginal complaints, CP IgA seropositivity was 41.6% versus 34.6% in patients without repeat angina (
P = .1057). The negative effect of CP on prognosis was confirmed after calculating the odds ratios for MACE (1.9, 95% CI 1.1–3.3). The rates of seropositivity for anti-CMV immunoglobulin G were not significantly different between both groups, although we found an association between infectious burden and repeat angina pectoris (odds ratio 1.8, 95% CI 1.1–3.0).
We conclude that preprocedural seropositivity of CP IgA is a risk factor for MACE and angina pectoris after PCI. Although no such relation was found for CMV alone, the cumulative infectious burden was also related to these clinical manifestations of restenosis.</description><subject>Angina pectoris</subject><subject>Angina Pectoris - etiology</subject><subject>Angioplasty</subject><subject>Angioplasty, Balloon, Coronary</subject><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Chlamydophila Infections - complications</subject><subject>Chlamydophila pneumoniae - isolation & purification</subject><subject>Coronary Artery Bypass</subject><subject>Coronary Disease - complications</subject><subject>Coronary Disease - therapy</subject><subject>Coronary heart disease</subject><subject>Coronary Restenosis - etiology</subject><subject>Cytomegalovirus</subject><subject>Cytomegalovirus - isolation & purification</subject><subject>Cytomegalovirus Infections - complications</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Fibrinolytic Agents - therapeutic use</subject><subject>Follow-Up Studies</subject><subject>Heart</subject><subject>Heart attacks</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Myocardial Infarction - etiology</subject><subject>Prognosis</subject><subject>Recurrence</subject><subject>Stents</subject><issn>0002-8703</issn><issn>1097-6744</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kd-q1DAQxoMonvXoA3gjAdG7rkmbpCleyeI_OOCNXofZZHpOSpusSbuwL-Bzm9KFA14IA2GS3zczmY-Q15ztOePqw7CHh2FfMyb2a3D9hOw469pKtUI8JTvGWF3pljU35EXOQ0lVrdVzcsOlkJ3suh35c7jMccJ7GOPZpyVTCI4eHkaYLs4DPQVcphg8IIVMTwmdt3NMmfYxUXBnTBkpnjHMmxLCvQ9Fhivly10_YyppsssMAWNpYGOKAdKF-lDeVqmP4SV51sOY8dX1vCW_vnz-efhW3f34-v3w6a6ygrVz1Vkpj2hVpxU0EvvGwRFQtPqIjjunLOoONNcdt40UvbJa942Vqu2Vk6LmzS15v9U9pfh7wTybyWeL47gNZ5Tq6lbrpoBv_wGHuKRQZjNcMiFkzTkrFN8om2LOCXtzSn4qnzOcmdUiM5hikVktMmtwXTRvrpWX44TuUXH1pADvrgBkC2OfIFifHznF21pJUbiPG4dlYWePyWTrMdjiUSr7Ny76_4zxF-c8sgg</recordid><startdate>20041001</startdate><enddate>20041001</enddate><creator>Rahel, Braim M.</creator><creator>Visseren, Frank L.J.</creator><creator>Suttorp, Maarten-Jan</creator><creator>Plokker, Thijs H.W.</creator><creator>Kelder, Johannes C.</creator><creator>de Jongh, Bartelt M.</creator><creator>Diepersloot, Rob J.A.</creator><creator>Verkooyen, Roel P.A.J.</creator><creator>Bouter, K.Paul</creator><general>Mosby, Inc</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20041001</creationdate><title>Cytomegalovirus and Chlamydia pneumoniae as predictors for adverse events and angina pectoris after percutaneous coronary intervention</title><author>Rahel, Braim M. ; Visseren, Frank L.J. ; Suttorp, Maarten-Jan ; Plokker, Thijs H.W. ; Kelder, Johannes C. ; de Jongh, Bartelt M. ; Diepersloot, Rob J.A. ; Verkooyen, Roel P.A.J. ; Bouter, K.Paul</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c407t-9c55bec6986a35ef3dabae478bed1dd6ce89a81891c354f6c88f3c567f6d54213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Angina pectoris</topic><topic>Angina Pectoris - etiology</topic><topic>Angioplasty</topic><topic>Angioplasty, Balloon, Coronary</topic><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Chlamydophila Infections - complications</topic><topic>Chlamydophila pneumoniae - isolation & purification</topic><topic>Coronary Artery Bypass</topic><topic>Coronary Disease - complications</topic><topic>Coronary Disease - therapy</topic><topic>Coronary heart disease</topic><topic>Coronary Restenosis - etiology</topic><topic>Cytomegalovirus</topic><topic>Cytomegalovirus - isolation & purification</topic><topic>Cytomegalovirus Infections - complications</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Fibrinolytic Agents - therapeutic use</topic><topic>Follow-Up Studies</topic><topic>Heart</topic><topic>Heart attacks</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Myocardial Infarction - etiology</topic><topic>Prognosis</topic><topic>Recurrence</topic><topic>Stents</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rahel, Braim M.</creatorcontrib><creatorcontrib>Visseren, Frank L.J.</creatorcontrib><creatorcontrib>Suttorp, Maarten-Jan</creatorcontrib><creatorcontrib>Plokker, Thijs H.W.</creatorcontrib><creatorcontrib>Kelder, Johannes C.</creatorcontrib><creatorcontrib>de Jongh, Bartelt M.</creatorcontrib><creatorcontrib>Diepersloot, Rob J.A.</creatorcontrib><creatorcontrib>Verkooyen, Roel P.A.J.</creatorcontrib><creatorcontrib>Bouter, K.Paul</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rahel, Braim M.</au><au>Visseren, Frank L.J.</au><au>Suttorp, Maarten-Jan</au><au>Plokker, Thijs H.W.</au><au>Kelder, Johannes C.</au><au>de Jongh, Bartelt M.</au><au>Diepersloot, Rob J.A.</au><au>Verkooyen, Roel P.A.J.</au><au>Bouter, K.Paul</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cytomegalovirus and Chlamydia pneumoniae as predictors for adverse events and angina pectoris after percutaneous coronary intervention</atitle><jtitle>The American heart journal</jtitle><addtitle>Am Heart J</addtitle><date>2004-10-01</date><risdate>2004</risdate><volume>148</volume><issue>4</issue><spage>670</spage><epage>675</epage><pages>670-675</pages><issn>0002-8703</issn><eissn>1097-6744</eissn><coden>AHJOA2</coden><abstract>The aim of our study was to investigate the influence of prior cytomegalovirus (CMV) or
Chlamydia pneumoniae (CP) infection on prognosis after percutaneous coronary intervention (PCI).
Using the enzyme-linked immunosorbent assay technique preprocedural anti-CMV immunoglobulin G and anti-CP immunoglobulin A (CP IgA), immunoglobulin M, and immunoglobulin G antibodies were measured. Repeat anginal complaints and major adverse clinical events (MACE), including PCI, coronary artery bypass grafting, myocardial infarction, and death, were recorded at 8-month follow-up.
Six hundred consecutive patients were included after successful PCI. Sixty-four percent of the patients were stented. The mean age was 61.6 years, and 68.9% were male. The rate of seropositivity for CP IgA in patients with MACE as compared with patients without MACE was 50.9% versus 35.4% (
P = .0276). In patients with repeat anginal complaints, CP IgA seropositivity was 41.6% versus 34.6% in patients without repeat angina (
P = .1057). The negative effect of CP on prognosis was confirmed after calculating the odds ratios for MACE (1.9, 95% CI 1.1–3.3). The rates of seropositivity for anti-CMV immunoglobulin G were not significantly different between both groups, although we found an association between infectious burden and repeat angina pectoris (odds ratio 1.8, 95% CI 1.1–3.0).
We conclude that preprocedural seropositivity of CP IgA is a risk factor for MACE and angina pectoris after PCI. Although no such relation was found for CMV alone, the cumulative infectious burden was also related to these clinical manifestations of restenosis.</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>15459599</pmid><doi>10.1016/j.ahj.2004.04.018</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-8703 |
| ispartof | The American heart journal, 2004-10, Vol.148 (4), p.670-675 |
| issn | 0002-8703 1097-6744 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66927883 |
| source | MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
| subjects | Angina pectoris Angina Pectoris - etiology Angioplasty Angioplasty, Balloon, Coronary Biological and medical sciences Cardiology. Vascular system Chlamydophila Infections - complications Chlamydophila pneumoniae - isolation & purification Coronary Artery Bypass Coronary Disease - complications Coronary Disease - therapy Coronary heart disease Coronary Restenosis - etiology Cytomegalovirus Cytomegalovirus - isolation & purification Cytomegalovirus Infections - complications Disease-Free Survival Female Fibrinolytic Agents - therapeutic use Follow-Up Studies Heart Heart attacks Humans Male Medical sciences Middle Aged Myocardial Infarction - etiology Prognosis Recurrence Stents |
| title | Cytomegalovirus and Chlamydia pneumoniae as predictors for adverse events and angina pectoris after percutaneous coronary intervention |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T20%3A21%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cytomegalovirus%20and%20Chlamydia%20pneumoniae%20as%20predictors%20for%20adverse%20events%20and%20angina%20pectoris%20after%20percutaneous%20coronary%20intervention&rft.jtitle=The%20American%20heart%20journal&rft.au=Rahel,%20Braim%20M.&rft.date=2004-10-01&rft.volume=148&rft.issue=4&rft.spage=670&rft.epage=675&rft.pages=670-675&rft.issn=0002-8703&rft.eissn=1097-6744&rft.coden=AHJOA2&rft_id=info:doi/10.1016/j.ahj.2004.04.018&rft_dat=%3Cproquest_cross%3E3237558881%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1504452110&rft_id=info:pmid/15459599&rft_els_id=S0002870304002194&rfr_iscdi=true |